LAUREMNESAL GAMOLO: Open Payments
NPI 1174290258 · REISTERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,664 in 173 payments from 24 companies in 2025. Trend: 2023 $31 · 2024 $2,845 · 2025 $5,664
Food & beverage: $4,811Travel & lodging: $776Education: $77
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $1,073 |
| Amgen Inc. | 19 | $938 |
| Eisai Inc. | 14 | $486 |
| ABBVIE INC. | 32 | $444 |
| Biogen, Inc. | 15 | $378 |
| Genentech USA, Inc. | 11 | $375 |
| Vanda Pharmaceuticals Inc. | 16 | $298 |
| Lundbeck LLC | 11 | $295 |
| PFIZER INC. | 14 | $256 |
| Janssen Biotech, Inc. | 4 | $187 |
Products named: KESIMPTA, UPLIZNA, Leqembi, PONVORY, VYEPTI, Ocrevus Zunovo, NURTEC ODT, VUMERITY.
Industry payments across MD — which companies pay providers there.
